A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis

(2017) B. J. Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor

(2017) T. E. Hutson et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma

(2010) Amado J. Zurita et al.   CANCER

Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

(2010) D. Huang et al.   CANCER RESEARCH

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2010) C. Pena et al.   CLINICAL CANCER RESEARCH

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon- : association of pretreatment serum levels with survival

(2009) A. J. Montero et al.   ANNALS OF ONCOLOGY

Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array

(2009) J L Perez-Gracia et al.   BRITISH JOURNAL OF CANCER

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer

(2009) E. O. Hanrahan et al.   CLINICAL CANCER RESEARCH

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer

(2009) Emer O. Hanrahan et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line bevacizumab combined with reduced dose interferon- 2a is active in patients with metastatic renal cell carcinoma

(2008) B. Melichar et al.   ANNALS OF ONCOLOGY

Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin

(2008) Sandra S. McAllister et al.   CELL

Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors

(2008) M. L. Nickerson et al.   CLINICAL CANCER RESEARCH

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY